Stock Events

Stock Events

Racura Oncology 

€1.66
0
+€0.02+1.22% Today

Statistics

Day High
1.66
Day Low
1.66
52W High
2.64
52W Low
0.56
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q4 2025
-0.01
0.32
0.65
0.99
Expected EPS
N/A
Actual EPS
-0.0131573626275

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FN3.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Race Oncology, including cancer treatments, making it a direct competitor.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including cancer, competing in the same market as Race Oncology.
AMGEN
AMGN
Mkt Cap189.22B
Amgen focuses on human therapeutics, including oncology/hematology, which pits it against Race Oncology in the cancer treatment sector.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs among other pharmaceuticals, directly competing with Race Oncology's offerings.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a research-based biopharmaceutical company with a broad range of cancer drugs, making it a competitor in the oncology market.
Novartis
NVS
Mkt Cap297.35B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, directly competing with Race Oncology.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG specializes in pharmaceuticals and diagnostics with a strong focus on oncology, making it a competitor in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca operates in the biopharmaceutical sector, focusing on the discovery and development of cancer treatments, competing in the same field as Race Oncology.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical segment, develops and sells oncology drugs, competing with Race Oncology in the healthcare market.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie is a research-driven biopharmaceutical company with a significant focus on oncology, making it a competitor in the cancer treatment market.

About

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Show more...
CEO
Dr. Peter M. Smith Ph.D.
Country
United States
ISIN
AU000000RAC3

Listings

MU
DE
FN3.MU
AU
AU
RAC.AU

0 Comments

Share your thoughts

FAQ

What is Racura Oncology stock price today?▼
The current price of FN3.MU is €1.66 EUR — it has increased by +1.22% in the past 24 hours. Watch Racura Oncology stock price performance more closely on the chart.
What is Racura Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Racura Oncology stocks are traded under the ticker FN3.MU.
Is Racura Oncology stock price growing?▼
FN3.MU stock has risen by +6.41% compared to the previous week, the month change is a +24.81% rise, over the last year Racura Oncology has showed a +193.81% increase.
When is the next Racura Oncology earnings date?▼
Racura Oncology is going to release the next earnings report on September 01, 2026.
What were Racura Oncology earnings last quarter?▼
FN3.MU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Racura Oncology located?▼
Racura Oncology operates in the Health & Wellness sector.
When did Racura Oncology complete a stock split?▼
Racura Oncology has not had any recent stock splits.
Where is Racura Oncology headquartered?▼
Racura Oncology is headquartered in Sydney, United States.